contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


maximilian-leroux-appointed-as-chief-commercial-officer-of-nightingale-health-plc

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Wouldn’t it make sense in Finland to test the entire population (adults) once a year, combined with a meeting (a nurse would suffice) for some hand-holding? The test would provide a solid basis for discussions on lifestyle changes etc. etc., even if Pera is unlikely to give up his sausage and beer or bother going for a jog. But people would always know to expect their “clinic visit” and would refrain from burdening the healthcare system in the meantime. It wouldn’t be any better or more effective care, but it would be billions cheaper than the current tinkering  We’re unlikely to see quick moves in Finland, but NH has opportunities in many other countries where change is seen as an opportunity.

True, that’s how it goes. What is the real price? Hardly that TT’s selling price, but I don’t believe that HVA gets it at the RRP (ovh) either.

Well, shouldn’t we talk about the actual price when discussing costs for, for example, a wellbeing services county? Homeros is just looking for more negativity there, as in all his other posts.

The predictive power of NG’s test should be compared to not making risk predictions at all. The whole point is that with NG’s technology, risk prediction can be done so affordably and with such low labor requirements that it is possible to do on a large scale.  Previous tools do not allow for this, and that is why population-level preventive healthcare risk assessments are not being done.

Well, it depends on which price we are talking about. Terveystalo sells that test for €199.

I won’t comment on these thoughts, but I will correct the price of that test: its RRP is €24 and the cost to NG is about €5. It’s funny in itself that Homeros doesn’t know this, even though he seems to know everything else.

The only savings tip so far is found in NG’s advertisements = it doesn’t actually exist. Small pilots in a couple of small wellbeing services counties will likely fail because of this.

Nightingale Health

Nightingale Health Plc Company release 8 May 2023 at 11:45 a.m. EESTNightingale Health Plc ("Nightingale Health") has appointed Maximilian LeRoux as Chief Commercial Officer. LeRoux will join...

Nightingale Health Plc Company release 8 May 2023 at 11:45&nbsp;a.m. EESTNightingale Health Plc ("Nightingale Health") has appointed Maximilian LeRoux as Chief Commercial Officer. LeRoux will join Nightingale Health's management team as of 1 August 2023 at the latest.LeRoux has over 20 years' experience of international business, and he has held a number of commercial leadership positions in sales and marketing, including at Dell Technologies (Texas, US), Savox Communications (Helsinki, Finland and New York, US) and others. LeRoux joins Nightingale Health from Mimi Hearing Technologies, a Berlin based scale-up company and the global leader in sound personalization and hearing wellbeing, where he held a position of Chief Commercial Officer. Before that he was the co-founder and CEO of AINA PTT a company providing critical communications solutions, building the company ground-up to a globally recognized brand within its industry.LeRoux holds a master's degree in economics from Goethe University in Frankfurt, Germany. At Nightingale Health, LeRoux will have a key role in growing the B2B sales in accordance with the company's ambitious targets.Teemu Suna, CEO and co-founder of Nightingale Health:"We are delighted to announce that Maximilian LeRoux will join Nightingale Health as CCO. LeRoux has experience of working in challenging positions at scale-up companies and larger corporations, as well as building a company from scratch to a successful business, which we highly value. He speaks five languages fluently and has lived and worked in numerous countries, and we believe he has excellent capabilities to grow Nightingale Health's global business."Maximilian LeRoux:"I am excited to join Nightingale Health as the CCO. I believe that my experience and skills will strengthen Nightingale Health's leadership team and I look forward to working together to achieve the company's vision, which can make a huge impact to the accessibility of preventative health. I am impressed by the service and product portfolio Nightingale Health has built, and I think it is the perfect timing to join the team to scale the sales globally."For further information, please contact:Teemu Suna, CEOir[at]nightingalehealth.comCertified Adviser:Oaklins Merasco Ltd, tel. +358 9 6129 670About Nightingale HealthNightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it's also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.